Altered endothelial dysfunction-related miRs in plasma from ME/CFS patients.
Blauensteiner, J, Bertinat, R, León, L E et al. · Scientific reports · 2021 · DOI
Quick Summary
This study looked at tiny molecules called microRNAs in the blood of ME/CFS patients to understand what might be going wrong with their blood vessels. The researchers found that five specific microRNAs were higher in ME/CFS patients compared to healthy people, and these molecules are known to affect how blood vessels function. This discovery suggests that blood vessel problems might be part of what causes ME/CFS symptoms.
Why It Matters
Blood vessel dysfunction is an underexplored aspect of ME/CFS that could explain symptoms like exercise intolerance and blood flow problems. Finding specific biomarkers related to endothelial dysfunction could lead to better diagnostic tests and new treatments targeting vascular health. This work opens a new research direction by connecting inflammation, blood vessels, and the molecular changes seen in ME/CFS.
Observed Findings
Five microRNAs (miR-21, miR-34a, miR-92a, miR-126, miR-200c) were jointly elevated in plasma from ME/CFS patients compared to healthy controls.
Similar microRNA elevation patterns were found in publicly available peripheral blood mononuclear cell data from ME/CFS patients.
Bioinformatics analysis linked these microRNAs to endothelial dysfunction pathways, oxidative stress, and oxygen regulation.
Histone deacetylase 1 emerged as a central protein node in the regulatory network of these microRNAs.
The microRNA changes suggest dysregulation of the Sirt1/eNOS axis, which normally maintains healthy blood vessel function.
Inferred Conclusions
Endothelial dysfunction may represent a previously underrecognized mechanism in ME/CFS pathogenesis.
The five identified microRNAs could serve as blood-based biomarkers for detecting blood vessel problems in ME/CFS patients.
Epigenetic mechanisms involving histone deacetylase activity may play a role in regulating endothelial function in ME/CFS.
Disruption of the anti-inflammatory Sirt1/eNOS signaling axis may contribute to vascular abnormalities in ME/CFS.
Remaining Questions
Do these elevated microRNAs directly cause endothelial dysfunction, or are they consequences of other disease processes?
What This Study Does Not Prove
This study shows correlation between elevated microRNAs and ME/CFS, but does not prove these molecules actually cause the disease or blood vessel problems. The findings are observational and do not establish whether correcting these microRNA levels would improve symptoms. It remains unclear whether these microRNA changes are primary drivers of ME/CFS or secondary consequences of other disease processes.